Back to Resources

Medical Design & Outsourcing

Women In Medtech

Conexeu

Architecting Bioregeneration™

The Women in Medtech edition of Medical Design & Outsourcing, featuring Conexeu Sciences co-founder and Chief Scientific Officer Dr. Claudia Chavez-Munoz, illustrates how innovators and leaders create a better industry and better outcomes for the patients they serve.

‍

‍

News and Media

Stay in the know about Conexeu, CXU and the future of regenerative science.

Medical Design & Outsourcing

October 1, 2026

Women In Medtech

Modern Aesthetics

October 7, 2026

Thinking Bigger About Regenerative Medicine

True bioregeneration should be scientifically defined by clear biological criteria, evidence spanning molecular signaling through organized tissue, and materials purposefully designed to support tissue regeneration.

Medical Design & Outsourcing

September 10, 2026

This Tissue Engineering Scientist is Bioprinting Next-Gen Absorbable Implants

Dr. Claudia Chavez-Munoz sees opportunities in breast cancer, wound care and GLP-1 patients with saggy skin.

September 26, 2026

The Reality of Ozempic Face: What You Need to Know

Ana Reisdorf, Registered Dietitian and GLP-1 user, talks with wound-healing scientist Brian Pilcher, PhD, about "Ozempic face" and the possibility of helping the body rebuild its own tissue.

StockTA Podcast

October 12, 2026

Conexeu Sciences (CNXU): The Roadmap for Its CXU™ Regenerative Platform

Conexeu Sciences (NASDAQ: CNXU) President and CEO Miles Harrison joins StockTA Managing Partner Kevin Steuer to discuss the company’s investigational CXU™ platform and its potential applications in regenerative tissue restoration.

October 15, 2026

Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors

Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company’s planned FDA 510(k) submission in the first quarter of 2027

October 6, 2026

Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027.

September 1, 2026

Conexeu Sciences Sets September and October 2026 Conference Schedule

Conexeu Sciences Inc. is pleased to announce its participation in the following investor and industry conferences during September and October 2026.

August 18, 2026

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu’s CXU™ Platform

Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison

IPO Edge examines where the next billion-dollar GLP-1 opportunity sits, and how Conexeu Sciences is positioning its CXU™ platform against it.

Dermatology Times

Dermatology Times Interview, Part 1: Conexeu Sciences Advances Bio-Regenerative ECM Platform for Structural Tissue Restoration

Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.

Regenerative Medicine's Next Leap: Conexeu Sciences CEO on Wound Care, Aesthetics & GLP-1s

CEO Miles Harrison breaks down how Conexeu's preclinical-stage platform targets wound care, medical aesthetics and a GLP-1-driven opportunity most investors are missing.

Practical Investing

Conexeu Sciences Inc. (CNXU) – A Biotech Stock Worth Watching

A follow-up Practical Investing segment on Conexeu Sciences (Nasdaq: CNXU) and the GLP-1-driven tissue-restoration opportunity.

Conexeu Sciences: The Regenerative Medicine Breakthrough That Could Transform Healthcare

CEO Miles Harrison on why the CXU™ platform is designed to create a biological scaffold the body can rebuild into, rather than replacing tissue with fillers or implants.

Progress, Potential and Possibilities

Regenerative Medicine Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, Conexeu Sciences

For decades, mastectomy patients have chosen between permanent implants and transplanted tissue. Dr. Claudia Chavez-Munoz discusses a third possibility — regenerating what was lost.

The GLP-1 Boom Is Reshaping Healthcare: What Comes Next?

Millions are losing weight with GLP-1 drugs. What happens after? A look at the changes in facial structure, skin quality and tissue support now being observed.

The Billion-Dollar Aesthetic Market is Being Reshaped by Weight Loss Drugs

Rapid, medication-driven weight loss goes far beyond the scale. A panel on the volume loss, skin laxity and structural tissue change the current aesthetic toolkit was never designed to address.

Stocks to Watch

Conexeu Sciences ($CNXU): The Future of Regenerative Aesthetics

President and CEO Miles Harrison on how Conexeu's platform could address the tissue-restoration demand created by GLP-1 weight-loss medications.

Stocks to Watch

Beyond Implants: How Conexeu’s ($CNXU) B.R.E.A.S.T.™ Could Advance Tissue Regeneration

Reconstruction is being redefined: Conexeu Sciences discusses B.R.E.A.S.T.™, a new approach designed to advance breast reconstruction following mastectomy.

This Stock Looks Like The Next 10-Bagger

ZipTrader looks at Conexeu Sciences (Nasdaq: CNXU) and its regenerative tissue platform.

GLP-1, Regenerative Medicine, and the Next Frontier of Medical Aesthetics

GLP-1 therapies are reshaping more than weight loss. Dr. Claudia Chavez-Munoz joins a panel on facial volume loss, skin laxity and broader changes in tissue health.

The Next Billion Dollar Category Coming to Regenerative Aesthetics?

President and CEO Miles Harrison discusses Conexeu's expansion into regenerative aesthetics, the CXU™ platform, the WFIRM collaboration, manufacturing scale-up and upcoming milestones.

Practical Investing

Conexeu Sciences (CNXU) New Catalyst & Latest Updates – Biotech Stock to Watch Now

Practical Investing profiles Conexeu Sciences (Nasdaq: CNXU) and its regenerative tissue platform.

Conexeu Sciences

Architecting Bioregeneration

Architecture is the shaping of space for human life — thoughtful, intentional, purposeful. Conexeu applies the same discipline to the body itself.

Conexeu Sciences

How the CXU™ platform works: one patented extracellular matrix formulation and one device, designed to scale across multiple markets without reformulation.

Conexeu Sciences

Conexeu Sciences introduces B.R.E.A.S.T.™, a 3D-bioprinted breast matrix built on the CXU™ platform and designed to advance reconstruction beyond implant-based replacement.

Conexeu Sciences

Conexeu Sciences: A Message from the CEO

A message from President and CEO Miles Harrison on what Architecting Bioregeneration™ means for the company and the patients it aims to serve.

Conexeu Sciences

An introduction to Conexeu Sciences and its patented bioregenerative extracellular matrix platform, CXU™, built on more than a decade of university research.

August 11, 2026

Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration

Conexeu Sciences Inc. (Nasdaq: CNXU) announced today that Dr. Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu Sciences, will present at the Controversies & Conversations in Laser & Cosmetic Surgery Symposium, taking place Aug. 14–16, 2026.

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It.

Conexeu Sciences is aiming CXU™ at the largest unclaimed frontier in injectable aesthetics: restoring body fullness at a scale today's fillers were never built to reach. The move builds on the company's completed 12-month P.R.O.O.F.™ preclinical study.

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill

Conexeu Completes 12-Month Preclinical P.R.O.O.F Study, Supporting Its Intended Move Into the $11 Billion Medical Aesthetics Market as a Platform¹

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Bell on Wednesday, June 10, 2026, at the Nasdaq MarketSite in New York City in celebration of its recent public listing and the commencement of trading under the ticker symbol "CNXU."

Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology

Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol “CNXU”

Public listing marks key milestone as Conexeu advances proprietary CXU™ platform and vision for regenerative medicine focused on biological restoration

Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants

Conexeu’s B.R.E.A.S.T.™ was developed using the Company’s proprietary CXU™ regenerative tissue platform to support gradual tissue remodeling

https://www.newsfilecorp.com/release/297413/Conexeu-Sciences-Unveils-Defining-Commitment-Architecting-BioregenerationTM

Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration™

Conexeu Sciences has made a deep commitment to the research, development, and infrastructure required to lead the next era of regenerative medicine, bringing together the Company's platform science and multi-application vision under one unifying idea, drawn from the discipline of architecture itself.

January 28, 2026

Why the GLP-1 Boom Demands a New Aesthetic Playbook

GLP-1s are now part of nearly every healthcare conversation and central to the obesity care landscape. In aesthetics, they are creating new demand for regenerative approaches that address soft-tissue changes associated with rapid weight loss.

October 16, 2025

Conexeu Sciences Closes Maximum $5M Reg CF Financing

Conexeu Sciences, Inc. closes a $5M Regulation Crowdfunding (Reg CF) financing round.

November 3, 2025

Conexeu Sciences Appoints Miles Harrison as President & Chief Executive Officer, To Shape the Future of True Tissue Regeneration

Miles D. Harrison joins Conexeu Sciences, Inc. as President & CEO.

November 5, 2025

Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell

Conexeu Sciences, Inc. appoints Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors.

November 20, 2025

Conexeu Sciences Signals a Major Breakthrough in ‘Personalized Human Tissue Creation’

Conexeu Sciences Inc. achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM).

SEE ALL RESOURCES

IMPORTANT NOTICES: CXU™ is a medical device candidate in preclinical development. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. Safety and effectiveness have not been established. See Forward-Looking Cautionary Statement.Terms such as 'next-generation,' 'advanced,' 'innovative,' and 'bioregenerative' reflect the Company's assessment of its technology relative to existing approaches and are not intended as representations of regulatory status, clinical performance, or guaranteed commercial outcomes. CXU™ is an investigational medical device candidate. Safety and effectiveness have not been established. See Forward-Looking Cautionary Statement.

© 2026 Conexeu. All Rights Reserved.

Conexeu is not affiliated with, endorsed by, or sponsored by any third-party brand referenced on this site. Ozempic®, Wegovy®, Dysport®, Sculptra®, Restylane®, Radiesse®, Xeomin®, Belotero®, Instalift®, Cetaphil®, Differin®, Proactiv® and Epiduo® are registered trademarks of their respective owners. CXU™, Ten-Minute Tissue™, B.R.E.A.S.T.™ and Architecting Bioregeneration™ are trademarks of Conexeu Sciences Inc.